Connect with us

Drilling News

Osisko Development Reports Underground Sampling Results

79.45 oz/t Au and 6.27 oz/t Ag over 5.5 ft. including 434.09 oz/t Au and 33.65 oz/t Ag over 1.0 ft.(2,724 g/t Au and 215.12 g/t Ag over 1.68 m including14,883.2…

Share this article:

Published

on

79.45 oz/t Au and 6.27 oz/t Ag over 5.5 ft. including 434.09 oz/t Au and 33.65 oz/t Ag over 1.0 ft.
(2,724 g/t Au and 215.12 g/t Ag over 1.68 m including
14,883.2 g/t Au and 1,153 g/t Ag over 0.30 m.)

MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) — Osisko Development Corp. (“Osisko Development” or the “Company”) is pleased to announce results from its ongoing underground exploration program on the recently acquired Tintic project and its 100% owned Trixie Mine (“Trixie”), as well as mineral claims covering more than 17,000 acres (including over 14,200 acres of which are patented) located in Central Utah’s historic Tintic Mining District (together with Trixie, the “Tintic Project”).

Summary

  • Trixie is one of several gold and base metal targets within the larger Tintic Project. The discovery of the T2 and T4 mineralized structures at Trixie in late 2020 by Tintic Consolidated Metals, LLC (“TCM”) showed gold (“Au”) and silver (“Ag”) grades associated with high sulphidation alteration hosted within quartzites that are capped by impermeable shales and volcanics.
  • Current underground mining activities at Trixie are directed by the exploration sampling and drilling results.
  • Results shown below are derived from 703 samples collected across a total of 183 sites (site ID 783 to 934) near the 625 ft level at Trixie across a total combined strike length of 650 ft. (~200 m). See Figure 1.
  • The sample results indicate anomalous gold results throughout the entire sampled area, and along exploration cross-cuts (Figure 1).
  • The mineralized structures remain open along strike and at depth and significant potential exists to expand the known mineralization.
  • The Company is currently expanding underground developments and utilizing one underground diamond drill rig and one surface reverse circulation rig to aid in the delineation of an initial mineral resource estimate by the end of Q4 2022. Results from this drilling program are pending.

Assay Highlights

  • 31.79 oz/t Au and 9.07 oz/t Ag over 4.8 ft. at site 738 (1,089.83 g/t Au and 310.93 g/t Ag over 1.46 m) including
  • 76.11 oz/t Au and 21.76 oz/t Ag over 2.0 ft. (2,609.65 g/t Au and 746.22 g/t Ag over 0.61 m)
  • 6.07 oz/t Au and 11.02 oz/t Ag over 9.0 ft. at site 742 (208.20 g/t Au and 377.87 g/t Ag over 2.74 m)
  • 10.28 oz/t Au and 8.60 oz/t Ag over 6.6 ft. at site 746 (352.56 g/t Au and 294.87 g/t Ag over 2.01 m) including
  • 26.28 oz/t Au and 21.01 oz/t Ag over 2.5 ft. (901.03 g/t Au and 720.25 g/t Ag over 0.76 m)
  • 9.03 oz/t Au and 9.72 oz/t Ag over 6.7 ft. at site 747 (309.48 g/t Au and 333.35 g/t Ag over 2.04 m)
  • 15.31 oz/t Au and 49.43 oz/t Ag over 4.8 ft. at site 787 (525.02 g/t Au and 1,694.76 g/t Ag over 1.46 m) including
  • 33.35 oz/t Au and 104.90 oz/t Ag over 2.0 ft. (1,143.35 g/t Au and 3,596.74 g/t Ag over 0.61 m)
  • 8.95 oz/t Au and 7.67 oz/t Ag over 16.0 ft. at site 792 (306.97 g/t Au and 262.91 g/t Ag over 4.88 m) including
  • 23.28 oz/t Au and 11.03 oz/t Ag over 2.0 ft. (798.05 g/t Au and 378.23 g/t Ag over 0.61 m)
  • 12.60 oz/t Au and 22.50 oz/t Ag over 4.0 ft. at site 878 (432.04 g/t Au and 771.44 g/t Ag over 1.22 m)
  • 4.62 oz/t Au and 6.95 oz/t Ag over 12.0 ft. at site 889 (158.23 g/t Au and 238.30 g/t Ag over 3.66 m)
  • 20.26 oz/t Au and 15.76 oz/t Ag over 6.4 ft. at site 893 (694.50 g/t Au and 540.37 g/t Ag over 1.95 m) including
  • 108.57 oz/t Au and 71.60 oz/t Ag over 1.1 ft. (3,722.31 g/t Au and 2,454.88 g/t Ag over 0.34 m)
  • 80.85 oz/t Au and 66.20 oz/t Ag over 4.5 ft. at site 896 (2,771.97 g/t Au and 2,269.69 g/t Ag over 1.3716 m) including
  • 157.23 oz/t Au and 128.17 oz/t Ag over 2.3 ft. (5,390.78 g/t Au and 4,394.48 g/t Ag over 0.70 m)
  • 11.97 oz/t Au and 17.20 oz/t Ag over 5.5 ft. at site 898 (410.31 g/t Au and 589.75 g/t Ag over 1.68 m) including
  • 41.72 oz/t Au and 59.72 oz/t Ag over 1.5 ft. (1,430.44 g/t Au and 2,047.51 g/t Ag over 0.46 m)
  • 17.70 oz/t Au and 7.11 oz/t Ag over 5.0 ft. at site 910 (606.75 g/t Au and 243.87 g/t Ag over 1.52 m) including
  • 51.03 oz/t Au and 13.35 oz/t Ag over 1.0 ft. (1,749.76 g/t Au and 457.69 g/t Ag over 0.30 m)
  • 33.61 oz/t Au and 6.25 oz/t Ag over 4.0 ft. at site 911 (1,152.40 g/t Au and 214.18 g/t Ag over 1.22 m) including
  • 121.05 oz/t Au and 12.42 oz/t Ag over 1.0 ft. (4,150.15 g/t Au and 425.99 g/t Ag over 0.30 m)
  • 79.45 oz/t Au and 6.27 oz/t Ag over 5.5 ft. at site 913 (2,724.03 g/t Au and 215.12 g/t Ag over 1.68 m) including
  • 434.09 oz/t Au and 33.65 oz/t Ag over 1.0 ft. (14,883.2 g/t Au and 1,153.72 g/t Ag over 0.30 m)
  • 16.63 oz/t Au and 2.49 oz/t Ag over 5.0 ft. at site 914 (570.32 g/t Au and 85.46 g/t Ag over 1.52 m) including
  • 26.47 oz/t Au and 3.86 oz/t Ag over 2.0 ft. (907.44 g/t Au and 132.26 g/t Ag over 0.61 m)

A length weighted composite for each face Site ID is shown in Table 1 and individual higher grade samples are also identified within the composite. Samples are collected in feet and assays are reported in g/t Au. Conversions to metric and imperial are rounded to two decimal places.

Chris Lodder, President of Osisko Development commented, “The Trixie underground sampling results from 2020 to present show exceptional continuity of high grades associated with the T2 structure. These 2022 samples along with the historic sampling by TCM, and in combination with the ongoing exploration developments within the present 720 ft strike by 175 ft vertical by 80 ft wide zone gives Osisko Development with a strong base for present mining activity and initial resources estimation. We will continue to use the present shaft / hoist at Trixie but we anticipate to increase access and mining capacity to the 625 ft and lower levels of Trixie through a new underground ramp initiated very recently and expected to reach the 625 ft level in Q1 2023.”

The T2 and T4 mineralized structures are associated with high-sulphidation epithermal mineralization, structurally controlled and hosted within the brittle Tintic Quartzite and capped by the impermeable shales of the Lower Ophir Formation. The T2 structure is 1 to 8 ft. wide (0.3 m to 2.4m) and mineralization consists of native Au, and rare Au-Ag – rich telluride minerals with quartz. The T4 is a mineralized stockwork zone ranging from to 10 to 80 ft. (3 m to 25 m) and located in the hanging wall of the T2 and is comprised of Au-Ag rich mineralization in host rock quartzite with quartz-barite-sulphosalt stockwork veining. Mineralization currently defined over 220 meters (720 feet) in strike and reports consistent multi-ounce gold grades along its entire strike length.

Face Sampling Methodology

As most structures at Trixie are steeply dipping to the east or west, current sampling procedures are designed to sample the structure. Channel samples are collected and do not exceed 3 ft. (1.0 m) in length. The face is washed for safety, and for better identification of mineralization, alteration and structures. The hangingwall and footwall of the structures are marked up on the face and back, samples intervals are marked up and follow lithological contacts.

For further information on Tintic, including additional production details please see the technical report on the Tintic Project, entitled “Technical Report on the Tintic Project, East Tintic Mining District, Utah County, Utah, USA”, dated June 10, 2022 (effective date of June 7, 2022), and filed at www.sedar.com under the profile of the Company.

Figure 1: 625 L Map with Select Assay Highlights  is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e1a09397-52ab-411b-ae55-c458f8ee95fb

Qualified Persons

Per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Maggie Layman, P.Geo. Vice President Exploration of Osisko Development Corp., is a Qualified Person and has prepared, validated, and approved the technical and scientific content of this news release.

Quality Assurance (QA)/Quality Control (QC)

All underground face samples are collected by TCM geologists from each of the active mining faces, with samples transported by the geologists from Trixie to the on-site TCM laboratory located at the Burgin administrative complex. Underground samples are dried, crushed to <10 mm and a 250 g split is taken. The split is pulverized, and a 30 g Fire Assay with gravimetric finish is completed to determine gold and silver grades, reported in oz./short ton and g/t.

The TCM Burgin laboratory is not a certified analytical laboratory, but the facility is managed by a qualified Laboratory Manager with annual auditing by technical staff. Inter-laboratory check assays using ALS Laboratory as a third-party independent analysis of samples is routinely carried out as part of ongoing QA/QC work. Certified OREAS Quality Control (“QC”) standards and blanks are inserted at regular intervals in the sample stream to monitor laboratory performance.

All drill core and exploration samples are dispatched to ALS Laboratory for offsite sample preparation and analysis. Samples are assigned a unique sample ID. All geological and sampling information is entered into Datashed database. Core is sawn in half and half are sampled. Certified standards and blanks inserted into all sample dispatches. Samples are collected by Old Dominion Transportation and dispatched to ALS Laboratory in Reno, NV. Sample submission forms accompany the samples, and digital copies emailed to ALS.

All sample preparation is completed by ALS, including crushing and pulverizing (Prep31) of samples. Analytical assay include gold and silver by fire assay of 50g sample with AAS finish (Au-AA26), over limits by gravimetric analysis (Au-Grav22). Multi element analysis is by four acid digest (ME-MS61). The pulps are returned to TCM and coarse rejects are disposed after 90 days. Assays are reported to TCM, and then loaded into Datashed, QA/QC samples are checked, and assays merged with sample information for future reporting.

Cautionary Statements

The Company cautions that the decision to commence production at Trixie in the form of small scale underground mining and batch vat leaching has been made without the benefit of a feasibility study, or reported mineral resources or mineral reserves, demonstrating economic and technical viability, and, as a result there may be increased uncertainty of achieving any particular level of recovery of material or the cost of such recovery. The Company cautions that historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that production will continue as anticipated or at all or that anticipated production costs will be achieved. The failure to continue production may have a material adverse impact on the Company’s ability to generate revenue and cash flow to fund operations. Failure to achieve the anticipated production costs may have a material adverse impact on the Company’s cash flow and potential profitability. In continuing current operations at Trixie after closing, the Company will not be basing its decision to continue such operations on a feasibility study, or reported mineral resources or mineral reserves demonstrating economic and technical viability. The Company cautions that mining at Trixie could be suspended at any time.

The Company is subject to the reporting requirements of the applicable Canadian securities laws, and as a result reports information regarding mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in the Tintic Technical Report and this news release, in accordance with Canadian reporting requirements, which are governed by NI 43-101. As such, such information concerning mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in the Tintic Technical Report and this news release, is not comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements of the SEC.

About Osisko Development Corp.

Osisko Development Corp. is uniquely positioned as a premier gold development company in North America to advance the Cariboo Gold Project and other Canadian, U.S.A. and Mexican properties, with the objective of becoming the next mid-tier gold producer. The Cariboo Gold Project, located in central British Columbia, Canada, is Osisko Development’s flagship asset. The considerable exploration potential at depth and along strike distinguishes the Cariboo Gold Project relative to other development assets. Osisko Development’s project pipeline is complemented by its interest in the San Antonio gold project, located in Sonora, Mexico and the Trixie gold test mine, located in Utah, U.S.A.

For further information about Osisko Development [(NYSE: ODV; TSX-V:ODV)], please visit www.osiskodevelopment.com or follow us on Twitter @OsiskoDev

Investor Contact:
Jean Francois Lemonde
VP, Investor Relations
[email protected]
Tel: 514-299-4926

Forward-looking Statements

Certain statements contained in this news release may be deemed “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. These forwardlooking statements, by their nature, require Osisko Development to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forwardlooking statements. Forwardlooking statements are not guarantees of performance. Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forwardlooking statements. Information contained in forwardlooking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, results of further exploration work to define and expand mineral resources, and that the deposit remains open for expansion at depth and down plunge, as well as other considerations that are believed to be appropriate in the circumstances, and any other information herein that is not a historical fact may be “forward looking information”. Material assumptions also include, management’s perceptions of historical trends, current conditions and expected future developments, results of further exploration work to define or expand any mineral resources, the ability to continue production at its Trixie mine, as well as other considerations that are believed to be appropriate in the circumstances. Osisko Development considers its assumptions to be reasonable based on information currently available, but cautions the reader that their assumptions regarding future events, many of which are beyond the control of Osisko Development, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect Osisko Development and its business. Such risks and uncertainties include, among others, risks relating to capital market conditions, the ability to continue current production, regulatory framework, the ability of exploration activities (including drill results) to accurately predict mineralization; errors in management’s geological modelling; the ability of to complete further exploration activities, including drilling; property and stream interests in the Project; the ability of the Company to obtain required approvals; the results of exploration activities; risks relating to exploration, development and mining activities; the global economic climate; metal prices; dilution; environmental risks; and community and non-governmental actions and the responses of relevant governments to the COVID-19 outbreak and the effectiveness of such responses. Readers are urged to consult the disclosure provided under the heading “Risk Factors” in the Company’s annual information form for the year ended December 31, 2021, as amended, which has been filed on SEDAR (www.sedar.com) under Osisko Development’s issuer profile and on the SEC’s EDGAR website (www.sec.gov), for further information regarding the risks and other factors applicable to the exploration results. Although the Company’s believes the expectations conveyed by the forward-looking statements are reasonable based on information available at the date of preparation, no assurances can be given as to future results, levels of activity and achievements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that these forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Table 1: 2022 Length Weighted Assay Composites at Trixie

 

 

Imperial Metric
Site ID   Depth from (ft.) Depth to (ft.) Length (ft.) Au oz/t Ag oz/t Depth from (m) Depth to (m) Length (m) Au (g/t) Ag (g/t)
738   0.0 4.8 4.8 31.79 9.07 0.00 1.46 1.46 1,089.83 310.93
738 including 1.5 3.5 2.0 76.11 21.76 0.46 1.07 0.61 2,609.65 746.22
739   0.0 8.3 8.3 0.97 2.29 0.00 2.53 2.53 33.29 78.47
739 including 3.0 5.7 2.7 1.34 4.41 0.91 1.74 0.82 45.88 151.30
739 and 5.7 6.9 1.2 2.51 4.60 1.74 2.10 0.37 85.92 157.86
740   0.0 4.0 4.0 4.73 5.66 0.00 1.22 1.22 162.22 194.22
740 including 2.3 4.0 1.7 11.13 13.33 0.70 1.22 0.52 381.60 456.97
741   0.0 2.7 2.7 0.43 0.00 0.00 0.82 0.82 14.78 0.01
741 including 1.2 2.4 1.2 0.95 0.00 0.37 0.73 0.37 32.66 0.01
742   0.0 9.0 9.0 6.07 11.02 0.00 2.74 2.74 208.20 377.87
742 including 4.0 7.3 3.3 3.09 6.42 1.22 2.23 1.01 105.98 220.16
742 and 7.3 9.0 1.7 25.99 45.88 2.23 2.74 0.52 890.97 1,573.11
743   0.0 3.7 3.7 4.58 2.04 0.00 1.13 1.13 156.97 70.03
743 including 0.0 1.5 1.5 10.01 5.04 0.00 0.46 0.46 343.03 172.73
744   0.0 6.6 6.6 5.00 2.45 0.00 2.01 2.01 171.39 84.05
744 including 1.5 3.8 2.3 13.87 5.24 0.46 1.16 0.70 475.69 179.60
745   0.0 7.7 7.7 1.32 2.12 0.00 2.35 2.35 45.12 72.86
745 including 4.2 6.7 2.5 3.48 5.50 1.28 2.04 0.76 119.33 188.62
746   0.0 6.6 6.6 10.28 8.60 0.00 2.01 2.01 352.56 294.87
746 including 2.3 4.8 2.5 26.28 21.01 0.70 1.46 0.76 901.03 720.25
747   0.0 6.7 6.7 9.03 9.72 0.00 2.04 2.04 309.48 333.35
747 including 0.0 1.2 1.2 30.54 21.52 0.00 0.37 0.37 1,047.03 737.97
747 and 1.2 2.3 1.1 16.59 29.89 0.37 0.70 0.34 568.84 1,024.73
747 and 2.3 3.3 1.0 1.02 2.85 0.70 1.01 0.30 35.14 97.67
747 and 5.5 6.7 1.2 3.23 1.87 1.68 2.04 0.37 110.78 64.02
748   0.0 5.4 5.4 0.65 1.19 0.00 1.65 1.65 22.12 40.93
748 including 1.9 3.0 1.1 3.13 5.17 0.58 0.91 0.34 107.19 177.21
749   0.0 5.4 5.4 1.26 1.89 0.00 1.65 1.65 43.25 64.78
749 including 2.3 4.4 2.1 2.96 4.54 0.70 1.34 0.64 101.61 155.54
750   0.0 5.0 5.0 1.13 2.91 0.00 1.52 1.52 38.90 99.93
750 including 2.4 3.4 1.0 5.50 14.57 0.73 1.04 0.30 188.41 499.62
751   0.0 6.0 6.0 0.13 0.26 0.00 1.83 1.83 4.29 8.91
751 including 2.8 5.0 2.2 0.27 0.46 0.85 1.52 0.67 9.13 15.75
752   0.0 5.0 5.0 0.13 0.47 0.00 1.52 1.52 4.51 15.96
753   0.0 11.4 11.4 3.02 6.73 0.00 3.47 3.47 103.67 230.61
753 including 2.0 3.5 1.5 0.66 2.42 0.61 1.07 0.46 22.63 82.93
753 and 3.5 5.4 1.9 8.10 19.11 1.07 1.65 0.58 277.65 655.33
753 and 5.4 7.4 2.0 2.25 6.65 1.65 2.26 0.61 77.24 227.91
753 and 7.4 9.2 1.8 0.54 1.69 2.26 2.80 0.55 18.62 58.11
753 and 9.2 10.4 1.2 10.33 16.63 2.80 3.17 0.37 354.13 570.24
754   0.0 4.2 4.2 0.08 0.22 0.00 1.28 1.28 2.73 7.68
755   0.0 3.0 3.0 0.20 0.92 0.00 0.91 0.91 6.85 31.50
755 including 2.3 3.0 0.7 0.73 2.11 0.70 0.91 0.21 24.90 72.40
756   0.0 3.5 3.5 0.10 0.14 0.00 1.07 1.07 3.33 4.91
756 including 1.0 2.0 1.0 0.28 0.26 0.30 0.61 0.30 9.66 8.98
757 No significant assays                    
758 No significant assays                    
759 No significant assays                    
760 No significant assays                    
761   0.0 3.7 3.7 0.06 0.32 0.00 1.13 1.13 2.02 10.99
761 including 1.7 2.0 0.3 0.43 1.01 0.52 0.61 0.09 14.63 34.65
762 No significant assays                    
763 No significant assays                    
764   91.0 111.0 20.0 0.06 0.23 27.74 33.83 6.10 1.91 8.04
764 including 97.0 99.0 2.0 0.52 0.00 29.57 30.18 0.61 17.86 0.01
769 No significant assays                    
770 No significant assays                    
771 No significant assays                    
772   0.0 5.0 5.0 0.09 0.24 0.00 1.52 1.52 3.24 8.08
772 including 2.7 3.5 0.8 0.57 1.37 0.82 1.07 0.24 19.40 46.90
773   0.0 10.4 10.4 0.04 1.76 0.00 3.17 3.17 1.23 60.33
773 including 7.9 9.4 1.5 0.24 10.01 2.41 2.87 0.46 8.26 343.34
774   0.0 8.5 8.5 0.01 0.59 0.00 2.59 2.59 0.51 20.07
774 including 8.0 8.5 0.5 0.07 5.69 2.44 2.59 0.15 2.43 195.17
775 No significant assays                    
776 No significant assays                    
777   0.0 8.0 8.0 0.07 0.23 0.00 2.44 2.44 2.50 8.00
777 including 5.0 8.0 3.0 0.18 0.45 1.52 2.44 0.91 6.09 15.58
778   0.0 7.0 7.0 0.31 0.59 0.00 2.13 2.13 10.65 20.22
778 including 0.0 3.4 3.4 0.30 0.00 0.00 1.04 1.04 10.18 0.01
778 and 3.4 5.0 1.6 0.72 2.58 1.04 1.52 0.49 24.64 88.42
779 No significant assays                    
780   0.0 4.3 4.3 3.26 2.56 0.00 1.31 1.31 111.90 87.77
780   0.0 2.0 2.0 6.99 5.50 0.00 0.61 0.61 239.49 188.69
781   0.0 8.0 8.0 0.55 1.05 0.00 2.44 2.44 18.82 35.96
781 including 3.0 4.0 1.0 4.31 7.86 0.91 1.22 0.30 147.65 269.39
782   0.0 3.0 3.0 1.29 1.84 0.00 0.91 0.91 44.11 63.25
783   0.0 7.5 7.5 0.03 0.24 0.00 2.29 2.29 1.08 8.20
783 including 6.1 7.0 0.9 0.15 1.17 1.86 2.13 0.27 5.14 40.26
784   0.0 3.6 3.6 0.27 3.27 0.00 1.10 1.10 9.22 112.27
784 including 0.0 0.6 0.6 0.35 4.36 0.00 0.18 0.18 11.94 149.52
784 and 0.6 1.6 1.0 0.62 6.04 0.18 0.49 0.30 21.20 207.01
785   0.0 8.1 8.1 0.07 0.56 0.00 2.47 2.47 2.50 19.14
785 including 1.2 4.8 3.6 0.15 0.97 0.37 1.46 1.10 5.25 33.32
786   0.0 3.2 3.2 1.36 5.25 0.00 0.98 0.98 46.74 180.17
786 including 2.4 3.2 0.8 4.19 6.27 0.73 0.98 0.24 143.56 214.94
787   0.0 4.8 4.8 15.31 49.43 0.00 1.46 1.46 525.02 1,694.76
787 including 0.0 0.8 0.8 8.41 32.15 0.00 0.24 0.24 288.38 1,102.30
787 and 0.8 2.8 2.0 33.35 104.90 0.24 0.85 0.61 1,143.35 3,596.74
788 No significant assays                    
790   0.0 2.5 2.5 4.09 26.72 0.00 0.76 0.76 140.11 916.14
790 including 0.0 1.5 1.5 6.13 40.27 0.00 0.46 0.46 210.11 1,380.78
791   0.0 14.0 14.0 0.61 0.44 0.00 4.27 4.27 20.89 14.99
791 including 2.0 4.0 2.0 3.76 1.92 0.61 1.22 0.61 129.04 65.86
792   0.0 16.0 16.0 8.95 7.67 0.00 4.88 4.88 306.97 262.91
792 including 4.0 6.0 2.0 18.50 23.32 1.22 1.83 0.61 634.42 799.42
792 and 6.0 8.0 2.0 17.32 16.21 1.83 2.44 0.61 593.69 555.85
792 and 10.0 12.0 2.0 4.43 2.95 3.05 3.66 0.61 151.73 101.06
792 and 12.0 14.0 2.0 3.52 0.66 3.66 4.27 0.61 120.84 22.49
792 and 14.0 16.0 2.0 23.28 11.03 4.27 4.88 0.61 798.05 378.23
793   0.0 5.0 5.0 0.44 2.96 0.00 1.52 1.52 15.25 101.41
793 including 0.0 3.5 3.5 0.63 3.39 0.00 1.07 1.07 21.56 116.15
794 No significant assays                    
795 No significant assays                    
796 No significant assays                    
797 No significant assays                    
798 No significant assays                    
799 No significant assays                    
800 No significant assays                    
801   0.0 6.0 6.0 0.19 0.60 0.00 1.83 1.83 6.55 20.55
801 including 4.0 4.6 0.6 0.52 1.33 1.22 1.40 0.18 17.84 45.43
801 and 5.3 6.0 0.7 0.81 3.70 1.62 1.83 0.21 27.83 126.97
802   0.0 4.9 4.9 0.36 1.72 0.00 1.49 1.49 12.29 58.84
802 including 2.4 4.9 2.5 0.65 3.24 0.73 1.49 0.76 22.33 111.01
803   0.0 5.1 5.1 0.17 3.06 0.00 1.55 1.55 5.81 104.89
805   0.0 6.5 6.5 1.68 0.93 0.00 1.98 1.98 57.66 32.04
805 including 0.0 3.5 3.5 0.34 0.38 0.00 1.07 1.07 11.58 13.12
805 and 3.5 5.5 2.0 4.07 2.07 1.07 1.68 0.61 139.59 71.05
805 and 5.5 6.5 1.0 1.61 0.59 1.68 1.98 0.30 55.06 20.21
806   0.0 6.0 6.0 0.02 0.43 0.00 1.83 1.83 0.54 14.91
806 including 0.0 0.5 0.5 0.09 1.20 0.00 0.15 0.15 3.15 41.02
807 No significant assays                    
810 No significant assays                    
811 No significant assays                    
812 No significant assays                    
813 No significant assays                    
814 No significant assays                    
815   0.0 6.5 6.5 1.36 2.31 0.00 1.98 1.98 46.77 79.13
815 including 3.0 4.5 1.5 0.65 1.42 0.91 1.37 0.46 22.24 48.53
815 and 4.5 6.5 2.0 3.95 6.07 1.37 1.98 0.61 135.31 208.23
816   0.0 5.9 5.9 0.17 1.08 0.00 1.80 1.80 5.76 37.17
816 including 4.9 5.9 1.0 0.47 0.86 1.49 1.80 0.30 16.25 29.45
817 No significant assays                    
818 No significant assays                    
819 No significant assays                    
820 No significant assays                    
821   0.0 4.0 4.0 0.87 2.77 0.00 1.22 1.22 29.89 94.81
821 including 0.0 2.4 2.4 1.16 2.54 0.00 0.73 0.73 39.76 86.99
821 and 2.4 3.4 1.0 0.68 4.79 0.73 1.04 0.30 23.28 164.31
822   0.0 4.7 4.7 0.23 0.51 0.00 1.43 1.43 7.92 17.37
822 including 0.0 1.0 1.0 1.06 2.25 0.00 0.30 0.30 36.24 77.12
823 No significant assays                    
824 No significant assays                    
825   0.0 4.4 4.4 0.08 1.03 0.00 1.34 1.34 2.69 35.23
825 including 2.8 3.8 1.0 0.26 3.16 0.85 1.16 0.30 9.05 108.22
826   0.0 5.7 5.7 0.08 0.60 0.00 1.74 1.74 2.84 20.52
826 including 1.5 3.0 1.5 0.19 1.07 0.46 0.91 0.46 6.58 36.68
827   0.0 4.9 4.9 0.04 0.60 0.00 1.49 1.49 1.28 20.40
828   0.0 8.0 8.0 0.06 0.64 0.00 2.44 2.44 2.12 22.08
828 including 6.0 8.0 2.0 0.25 2.24 1.83 2.44 0.61 8.43 76.83
829 No significant assays                    
830 No significant assays                    
831 No significant assays                    
832   0.0 14.0 14.0 1.30 3.33 0.00 4.27 4.27 44.67 114.18
832 including 0.0 2.0 2.0 0.49 0.20 0.00 0.61 0.61 16.73 6.82
832 and 6.0 8.0 2.0 1.13 11.25 1.83 2.44 0.61 38.66 385.61
832 and 8.0 10.0 2.0 6.54 10.32 2.44 3.05 0.61 224.19 353.74
832 and 10.0 12.0 2.0 0.72 1.38 3.05 3.66 0.61 24.81 47.22
833   0.0 14.0 14.0 0.33 0.70 0.00 4.27 4.27 11.29 24.13
833 including 4.0 6.0 2.0 0.23 0.89 1.22 1.83 0.61 8.02 30.53
833 and 6.0 8.0 2.0 1.50 2.86 1.83 2.44 0.61 51.47 98.08
833 and 12.0 14.0 2.0 0.51 0.33 3.66 4.27 0.61 17.58 11.27
834 No significant assays                    
835 No significant assays                    
836   0.0 3.9 3.9 0.03 1.78 0.00 1.19 1.19 0.95 60.88
837 No significant assays                    
838   0.0 18.0 18.0 0.33 1.57 0.00 5.49 5.49 11.33 53.96
838 including 0.0 3.0 3.0 0.72 3.69 0.00 0.91 0.91 24.85 126.64
838 and 6.0 9.0 3.0 1.07 4.18 1.83 2.74 0.91 36.54 143.16
840 No significant assays                    
841 No significant assays                    
842 No significant assays                    
843   0.0 6.2 6.2 0.04 1.10 0.00 1.89 1.89 1.54 37.82
844 No significant assays                    
845   0.0 4.5 4.5 0.09 0.39 0.00 1.37 1.37 3.08 13.50
845 including 2.0 4.5 2.5 0.15 0.53 0.61 1.37 0.76 5.21 18.14
846   0.0 7.0 7.0 0.19 0.76 0.00 2.13 2.13 6.58 26.17
846 including 4.0 7.0 3.0 0.42 1.29 1.22 2.13 0.91 14.33 44.09
847   0.0 7.0 7.0 0.95 2.58 0.00 2.13 2.13 32.45 88.39
847 including 5.5 7.0 1.5 4.22 11.38 1.68 2.13 0.46 144.74 390.30
848   0.0 6.0 5.4 3.87 4.30 0.00 1.83 1.65 132.68 147.32
848 including 0.0 2.6 2.6 3.44 6.28 0.00 0.79 0.79 118.10 215.46
848 and 2.6 5.0 2.4 4.97 2.86 0.79 1.52 0.73 170.41 98.05
849   0.0 6.4 6.4 0.73 3.13 0.00 1.95 1.95 24.96 107.31
849 including 3.0 5.0 2.0 1.99 6.74 0.91 1.52 0.61 68.22 231.13
850   0.0 4.8 4.8 4.28 3.18 0.00 1.46 1.46 146.80 108.93
850 including 1.7 2.4 0.7 28.02 16.58 0.52 0.73 0.21 960.82 568.50
851   0.0 3.0 3.0 0.17 0.86 0.00 0.91 0.91 5.84 29.48
851 including 2.0 3.0 1.0 0.39 1.36 0.61 0.91 0.30 13.40 46.79
852   0.0 5.7 5.7 0.17 1.65 0.00 1.74 1.74 5.78 56.70
852 including 4.7 5.7 1.0 0.78 0.78 1.43 1.74 0.30 26.64 26.77
853   0.0 4.0 4.0 0.40 1.64 0.00 1.22 1.22 13.75 56.29
853 including 0.0 1.0 1.0 0.93 4.49 0.00 0.30 0.30 31.95 153.93
853 and 2.0 3.0 1.0 0.36 0.65 0.61 0.91 0.30 12.34 22.39
854   0.0 5.7 5.7 0.82 1.94 0.00 1.74 1.74 28.12 66.67
854 including 0.0 0.7 0.7 4.06 6.82 0.00 0.21 0.21 139.05 233.94
854 and 2.3 5.1 2.8 0.54 1.61 0.70 1.55 0.85 18.68 55.13
855   0.0 4.7 4.7 0.27 3.18 0.00 1.43 1.43 9.42 108.95
855 including 0.0 1.2 1.2 0.54 8.77 0.00 0.37 0.37 18.35 300.72
856   0.0 4.7 4.7 1.50 0.96 0.00 1.43 1.43 51.26 32.85
856 including 3.0 4.7 1.7 4.03 0.00 0.91 1.43 0.52 138.10 0.01
857   0.0 4.6 4.6 0.43 5.48 0.00 1.40 1.40 14.65 187.93
857 including 0.0 1.8 1.8 0.22 4.21 0.00 0.55 0.55 7.68 144.35
857 and 3.3 4.6 1.3 1.08 9.83 1.01 1.40 0.40 37.18 337.05
858   0.0 3.3 3.3 0.07 1.23 0.00 1.01 1.01 2.42 42.33
859   0.0 3.2 3.2 0.03 1.06 0.00 0.98 0.98 1.17 36.35
860   0.0 8.0 8.0 0.62 5.76 0.00 2.44 2.44 21.13 197.56
860 including 0.0 2.0 2.0 1.80 3.25 0.00 0.61 0.61 61.62 111.48
860 and 2.0 4.0 2.0 0.67 19.55 0.61 1.22 0.61 22.86 670.29
861   0.0 8.0 8.0 0.24 0.33 0.00 2.44 2.44 8.23 11.39
861 including 0.0 2.0 2.0 0.93 0.98 0.00 0.61 0.61 31.97 33.45
862 No significant assays                    
863   0.0 2.3 2.3 5.44 3.18 0.00 0.70 0.70 186.58 108.93
863 including 0.0 0.7 0.7 17.68 9.77 0.00 0.21 0.21 606.14 334.95
864   0.0 6.3 6.3 0.12 2.17 0.00 1.92 1.92 4.22 74.49
864 including 3.5 5.8 2.3 0.30 3.01 1.07 1.77 0.70 10.18 103.26
865 No significant assays                    
866 No significant assays                    
867   0.0 6.0 6.0 0.26 0.75 0.00 1.83 1.83 8.89 25.63
867 including 0.0 3.0 3.0 0.37 0.83 0.00 0.91 0.91 12.68 28.58
868 No significant assays                    
869   0.0 4.0 4.0 3.76 10.87 0.00 1.22 1.22 128.78 372.67
869 including 1.5 4.0 2.5 6.00 16.42 0.46 1.22 0.76 205.62 563.01
870   0.0 5.0 5.0 1.23 4.42 0.00 1.52 1.52 42.22 151.53
870 including 0.0 2.0 2.0 3.06 10.98 0.00 0.61 0.61 105.03 376.40
871   0.0 3.5 3.5 0.39 1.25 0.00 1.07 1.07 13.21 42.81
871 including 1.0 2.5 1.5 0.89 2.79 0.30 0.76 0.46 30.48 95.68
872   0.0 8.0 8.0 0.38 0.96 0.00 2.44 2.44 12.97 32.82
872 including 4.0 6.0 2.0 0.68 1.32 1.22 1.83 0.61 23.48 45.25
873   0.0 6.1 6.1 1.03 4.97 0.00 1.86 1.86 35.33 170.36
873 including 1.4 2.1 0.7 5.80 16.69 0.43 0.64 0.21 198.80 572.20
874   0.0 3.7 3.7 3.74 90.25 0.00 1.13 1.13 128.11 3,094.36
874 including 0.0 1.9 1.9 6.51 50.45 0.00 0.56 0.56 223.23 1,729.77
875   0.0 6.0 6.0 0.12 0.28 0.00 1.83 1.83 4.18 9.65
876   0.0 6.0 6.0 0.32 0.98 0.00 1.83 1.83 10.83 33.51
876 including 0.0 3.0 3.0 0.57 1.15 0.00 0.91 0.91 19.39 39.50
877   0.0 3.0 3.0 5.13 35.08 0.00 0.91 0.91 175.74 1,202.83
877 including 0.0 2.0 2.0 7.23 48.68 0.00 0.61 0.61 247.93 1,669.10
878   0.0 4.0 4.0 12.60 22.50 0.00 1.22 1.22 432.04 771.44
878 including 0.0 0.6 0.6 15.61 29.49 0.00 0.18 0.18 535.28 1,011.18
878 and 0.6 1.6 1.0 16.55 72.09 0.18 0.49 0.30 567.26 2,471.51
878 and 1.6 3.0 1.4 17.25 0.00 0.49 0.91 0.43 591.50 0.01
879   0.0 4.4 4.4 5.33 2.63 0.00 1.34 1.34 182.61 90.14
879 including 0.0 1.6 1.6 14.43 5.97 0.00 0.49 0.49 494.63 204.62
880 No significant assays                    
881   0.0 4.8 4.8 0.05 0.27 0.00 1.46 1.46 1.72 9.34
881 including 0.0 1.0 1.0 0.19 0.90 0.00 0.30 0.30 6.51 30.75
882   0.0 8.0 8.0 0.24 0.63 0.00 2.44 2.44 8.39 21.76
882 including 4.0 6.0 2.0 0.51 0.69 1.22 1.83 0.61 17.45 23.79
883 No significant assays                    
884   0.0 6.0 6.0 0.37 2.37 0.00 1.83 1.83 12.64 81.22
884 including 0.0 3.0 3.0 0.49 4.32 0.00 0.91 0.91 16.80 147.99
885   0.0 4.0 4.0 0.26 3.62 0.00 1.22 1.22 8.77 124.11
885 including 1.0 2.0 1.0 0.31 2.62 0.30 0.61 0.30 10.66 89.86
885 and 3.0 4.0 1.0 0.48 8.37 0.91 1.22 0.30 16.44 286.81
886 No significant assays                    
887   0.0 6.7 6.7 4.25 18.95 0.00 2.04 2.04 145.78 649.80
887 including 2.8 4.0 1.2 17.81 46.14 0.85 1.22 0.37 610.55 1,581.85
889   0.0 12.0 12.0 4.62 6.95 0.00 3.66 3.66 158.23 238.30
889 including 0.0 2.0 2.0 2.65 1.83 0.00 0.61 0.61 90.81 62.70
889 and 4.0 6.0 2.0 13.56 15.34 1.22 1.83 0.61 464.83 525.95
889 and 6.0 8.0 2.0 9.56 20.49 1.83 2.44 0.61 327.84 702.40
889 and 8.0 10.0 2.0 0.69 1.91 2.44 3.05 0.61 23.65 65.55
889 and 10.0 12.0 2.0 0.91 1.42 3.05 3.66 0.61 31.33 48.71
890 No significant assays                    
891 No significant assays                    
892 No significant assays                    
893   0.0 6.4 6.4 20.26 15.76 0.00 1.95 1.95 694.50 540.37
893 including 0.0 3.5 3.5 2.60 5.47 0.00 1.07 1.07 89.06 187.48
893 and 3.5 4.6 1.1 108.57 71.60 1.07 1.40 0.34 3,722.31 2,454.88
894 No significant assays                    
895   0.0 10.0 10.0 0.05 0.24 0.00 3.05 3.05 1.67 8.40
895 including 0.0 2.0 2.0 0.21 1.05 0.00 0.61 0.61 7.31 35.83
896   0.0 4.5 4.5 80.85 66.20 0.00 1.37 1.37 2,771.97 2,269.69
896 including 1.0 3.3 2.3 157.23 128.17 0.30 1.01 0.70 5,390.78 4,394.48
898   0.0 5.5 5.5 11.97 17.20 0.00 1.68 1.68 410.31 589.75
898 including 3.0 4.5 1.5 41.72 59.72 0.91 1.37 0.46 1,430.44 2,047.51
898 and 4.5 5.5 1.0 2.95 4.99 1.37 1.68 0.30 101.17 171.13
899   0.0 1.8 1.8 2.16 1.40 0.00 0.55 0.55 73.96 48.00
899 including 1.3 1.8 0.5 7.63 4.75 0.40 0.55 0.15 261.43 163.01
900   0.0 1.4 1.4 0.65 6.07 0.00 0.43 0.43 22.42 208.16
901   0.0 2.0 2.0 1.25 4.38 0.00 0.61 0.61 42.96 150.09
902 No significant assays                    
903 No significant assays                    
904 No significant assays                    
905   0.0 12.0 12.0 0.21 0.71 0.00 3.66 3.66 7.24 24.37
905 including 0.0 3.0 3.0 0.72 1.63 0.00 0.91 0.91 24.56 55.81
906   0.0 12.0 12.0 1.33 3.10 0.00 3.66 3.66 45.58 106.23
906 including 3.0 6.0 3.0 2.40 6.86 0.91 1.83 0.91 82.21 235.04
906 and 9.0 12.0 3.0 2.11 3.63 2.74 3.66 0.91 72.40 124.37
907 No significant assays                    
908 No significant assays                    
909   0.0 5.0 5.0 0.55 0.82 0.00 1.52 1.52 18.73 28.27
909 including 0.0 1.6 1.6 0.57 0.71 0.00 0.49 0.49 19.63 24.19
909 and 1.6 3.0 1.4 1.30 1.73 0.49 0.91 0.43 44.44 59.19
910   0.0 5.0 5.0 17.70 7.11 0.00 1.52 1.52 606.75 243.87
910 including 0.0 2.0 2.0 12.55 6.64 0.00 0.61 0.61 430.14 227.71
910 and 2.0 3.0 1.0 51.03 13.35 0.61 0.91 0.30 1,749.76 457.69
910 and 3.0 5.0 2.0 6.18 4.47 0.91 1.52 0.61 211.86 153.12
911   0.0 4.0 4.0 33.61 6.25 0.00 1.22 1.22 1,152.40 214.18
911 including 1.0 2.0 1.0 121.05 12.42 0.30 0.61 0.30 4,150.15 425.99
911 and 2.0 4.0 2.0 6.58 5.98 0.61 1.22 0.61 225.55 205.14
912   0.0 8.0 8.0 0.10 0.50 0.00 2.44 2.44 3.41 17.12
912 including 0.0 2.0 2.0 0.37 0.75 0.00 0.61 0.61 12.75 25.74
913   0.0 5.5 5.5 79.45 6.27 0.00 1.68 1.68 2,724.03 215.12
913 including 1.8 2.8 1.0 434.09 33.65 0.55 0.85 0.30 14,883.20 1,153.72
914   0.0 5.0 5.0 16.63 2.49 0.00 1.52 1.52 570.32 85.46
914 including 0.0 2.0 2.0 26.47 3.86 0.00 0.61 0.61 907.44 132.26
914 and 2.0 3.0 1.0 24.70 2.38 0.61 0.91 0.30 846.79 81.52
914 and 3.0 5.0 2.0 2.77 1.18 0.91 1.52 0.61 94.96 40.62
915 No significant assays                    
916   0.0 20.0 20.0 0.17 32.70 0.00 6.10 6.10 5.66 1,121.28
916 including 4.0 6.0 2.0 0.83 1.42 1.22 1.83 0.61 28.36 48.73
916 and 16.0 18.0 2.0 0.20 322.38 4.88 5.49 0.61 7.01 11,053.15
917   0.0 4.5 4.5 3.40 5.03 0.00 1.37 1.37 116.71 172.46
917 including 0.0 1.3 1.3 2.89 1.56 0.00 0.40 0.40 98.93 53.44
917 and 1.3 2.6 1.3 8.47 14.44 0.40 0.79 0.40 290.57 495.25
918   0.0 20.0 20.0 0.23 1.55 0.00 6.10 6.10 7.78 53.15
918 including 2.0 4.0 2.0 1.24 2.52 0.61 1.22 0.61 42.45 86.47
919   0.0 12.0 12.0 0.16 4.41 0.00 3.66 3.66 5.65 151.22
919 including 10.0 12.0 2.0 0.47 3.04 3.05 3.66 0.61 16.23 104.22
920   0.0 12.0 12.0 0.06 1.22 0.00 3.66 3.66 2.16 41.67
921   0.0 4.0 4.0 0.57 1.87 0.00 1.22 1.22 19.49 63.96
921 including 1.6 3.3 1.7 1.31 4.30 0.49 1.01 0.52 44.81 147.42
922   0.0 4.9 4.9 0.33 0.39 0.00 1.49 1.49 11.45 13.23
922 including 0.0 2.2 2.2 0.47 0.31 0.00 0.67 0.67 16.21 10.69
922 and 2.2 3.2 1.0 0.57 0.98 0.67 0.98 0.30 19.57 33.45
923 No significant assays                    
924   0.0 3.8 3.8 0.31 0.57 0.00 1.16 1.16 10.61 19.64
924 including 1.4 2.2 0.8 1.45 2.67 0.43 0.67 0.24 49.55 91.54
925   0.0 16.0 16.0 0.13 2.71 0.00 4.88 4.88 4.53 93.08
925 including 10.0 12.0 2.0 0.72 14.77 3.05 3.66 0.61 24.72 506.27
926   0.0 16.0 16.0 0.21 2.17 0.00 4.88 4.88 7.04 74.45
926 including 4.0 6.0 2.0 0.66 7.21 1.22 1.83 0.61 22.76 247.31
926 and 10.0 12.0 2.0 0.36 0.64 3.05 3.66 0.61 12.51 21.80
927   0.0 5.3 5.3 2.83 1.40 0.00 1.62 1.62 97.18 48.12
927   0.8 1.8 1.0 14.57 7.44 0.24 0.55 0.30 499.55 254.97
928 No significant assays       0.00 0.00 0.00 0.00 0.00    
929   0.0 4.0 4.0 0.23 0.50 0.00 1.22 1.22 8.01 17.07
929 including 0.0 3.0 3.0 0.31 0.66 0.00 0.91 0.91 10.63 22.76
930   0.0 90.0 90.0 0.06 0.72 0.00 27.43 27.43 2.17 24.53
930 including 25.0 30.0 5.0 0.29 0.00 7.62 9.14 1.52 10.11 0.01
930 and 55.0 60.0 5.0 0.43 10.19 16.76 18.29 1.52 14.67 349.50
931 No significant assays                    
932 No significant assays                    
933 No significant assays                    
934   0.0 6.0 6.0 0.02 0.31 0.00 1.83 1.83 0.75 10.58

drill results
drilling
tsxv-odv
osisko-development-corp
osisko development corp
press-release

Share this article:

Companies

Nevada Exploration Provides Project Updates and Seeks Expressions of Interest

VANCOUVER, British Columbia, Aug. 26, 2022 (GLOBE NEWSWIRE) — Nevada Exploration Inc. (“NGE” or the “Company”) (TSX-V:NGE; OTCQB:NVDEF) provides…

Share this article:

Continue Reading
Drilling News

Nevada Exploration Announces Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 29, 2022 (GLOBE NEWSWIRE)…

Share this article:

Continue Reading
Drilling News

Aton announces the first results and completion of the resource infill RC drilling programme at Hamama West

VANCOUVER, British Columbia, Aug. 26, 2022 (GLOBE NEWSWIRE) — Aton Resources Inc. (AAN: TSX-V) (“Aton” or the “Company") is pleased to update…

Share this article:

Continue Reading

Trending